Abiopharma

🔍 Rangel Danielle (Executive)

Company: STANDEX INTERNATIONAL CORP/DE/ (SXI)

Report Date: 2026-08-23

Detailed Transactions and Holdings:

• Acquired 85 shares of Common Stock (Direct)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 293.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 26 shares of Common Stock at $310.28 per share (Direct)
  Date: 2026-08-21 | Code: F | equity_swap_involved: 0 | shares_owned_after: 267.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 12 shares of Common Stock at $310.28 per share (Direct)
  Date: 2026-08-21 | Code: F | equity_swap_involved: 0 | shares_owned_after: 255.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 39 shares of Common Stock (Direct)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 294.00 | transaction_form_type: 4 | Footnotes: F3, F3
• Sold 11 shares of Common Stock at $310.28 per share (Direct)
  Date: 2026-08-21 | Code: F | equity_swap_involved: 0 | shares_owned_after: 283.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 69 shares of Common Stock (Direct)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 352.00 | transaction_form_type: 4 | Footnotes: F3, F3
• Sold 19 shares of Common Stock at $310.28 per share (Direct)
  Date: 2026-08-21 | Code: F | equity_swap_involved: 0 | shares_owned_after: 333.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 85 shares of Phantom Stock Units (Derivative)
  Date: 2026-08-21 | Code: M | Expires: 2026-08-23 | Exercise: 2026-08-23 | equity_swap_involved: 0 | shares_owned_after: 40.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1
• Sold 40 shares of Phantom Stock Units (Derivative)
  Date: 2026-08-21 | Code: D | Expires: 2026-08-23 | Exercise: 2026-08-23 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F4, F4
• Sold 39 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 39.00 | transaction_form_type: 4 | Footnotes: F3, F3, F3, F3, F3
• Sold 69 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 138.00 | transaction_form_type: 4 | Footnotes: F3, F3, F3, F3, F3
• Acquired 146 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-23 | Code: A | equity_swap_involved: 0 | shares_owned_after: 146.00 | transaction_form_type: 4 | Footnotes: F5, F5, F5, F5, F5
• Acquired 146 shares of Phantom Stock Units (Derivative)
  Date: 2026-08-23 | Code: A | Expires: 2029-08-23 | Exercise: 2029-08-23 | equity_swap_involved: 0 | shares_owned_after: 146.00 | transaction_form_type: 4 | Footnotes: F6, F6, F6

Footnotes:

• F1: Vesting of Phantom Stock pursuant to the Company's 2018 Omnibus Incentive Plan. Actual achievement, which could have ranged from 0% to 250% of the award, was 68%. The transaction reported herein is the actual number of shares vesting pursuant thereto.
• F2: Shares sold to pay taxes on vesting of previously issued restricted stock and/or performance share units.
• F3: Vesting of Restricted Stock Units pursuant to the Company's 2018 Omnibus Incentive Plan.
• F4: Vesting of Phantom Stock pursuant to the Company's 2018 Omnibus Incentive Plan. Actual achievement, which could have ranged from 0% to 250% of the award, was 68%. Phantom Stock Units were granted at 100% achievement, so this transaction reflects the disposition of shares to accurately reflect the vesting.
• F5: Grant of Restricted Stock Units pursuant to the 2018 Omnibus Incentive Plan of the Company which vests one-third per year on each anniversary of the date of the award.
• F6: Award of Performance Share Units pursuant to the 2018 Omnibus Incentive Plan of the Company. These shares cliff vest at the end of a three year performance period with the ultimate number of shares ranging from 0 to 250% of the award based on achievement against Company performance metrics of the three year period.